Patients with different solid tumours, including NSCLC (without prior anti-PD-1/PD-L1 therapy), were enrolled in a trial with sabatolimab (MBG453), an anti-TIM-3 mAb, alone and in combination with spartalizumab (anti-PD-1 antibody, PDR001). The gene discussed is CD274; the disease is non-small cell lung carcinoma.